Technology evaluation: Theratope, Biomira Inc

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 4, 2000, Pages 453-458

  Morse, M A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DRUG CARRIER; GLYCAN DERIVATIVE; IMMUNOLOGICAL ADJUVANT; SIALIC ACID DERIVATIVE; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRANULOMA; HUMAN; MULTICENTER STUDY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; STOMACH CARCINOMA; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOTECHNOLOGY; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HEMOCYANIN; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS;

MURINAE;

EID: 0033847704     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Biomira's cancer vaccine results
2. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients
3. Biomira's first revenues from Chiron deal
4. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
5. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific Immunotherapy
6. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
7. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarlan cancer patients: Correlations with survival following active specific immunotherapy
8. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus DETOX adjuvant
9. Evidence of a cellular Immune response against sialyl-Tn In breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
10. Oligosaccharide differences in the DF3 sialomucln antigen from normal human milk and the BT-20 human breast carcinoma cell line
11. O-linked mucin-type glycoproteins in normal and malignant colon mucosa: Lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas
12. Sialyl Tn as a prognostic marker in epithelial ovarian cancer
13. The prognostic significance of slalyl-Tn antigen In women treated with breast carcinoma treated with adjuvant chemotherapy
14. Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer
15. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate
16. Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis
17. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant
18. A randomized phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
19. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells